| Literature DB >> 30159196 |
Vinit V Gholap1, Leon Kosmider1,2, Matthew S Halquist1.
Abstract
The use of electronic cigarettes (e-cigarettes) is a growing trend in population. E-cigarettes are evolving at a rapid rate with variety of battery powered devices and combustible nicotine refills such as e-liquids. In contrast to conventional cigarettes which are studied well for their toxicity and health effects, long-term clinical data on e-cigarettes are not available yet. Therefore, safety of e-cigarettes is still a major concern. Although the Food and Drug Administration (FDA) has recently started regulating e-cigarette products, no limits on nicotine and other ingredients in such products have been proposed. Considering the regulatory requirements, it is critical that reliable and standardized analytical methods for analyzing nicotine and other ingredients in e-cigarette products such as e-liquids are available. Here, we are reporting a fully validated high-performance liquid chromatography (HPLC) method based on nicotine peak purity for accurately quantifying nicotine in various e-liquids. The method has been validated as per ICH Q2(R1) and USP <1225> guidelines. The method is specific, precise, accurate, and linear to analyze nicotine in e-liquids with 1 to >50 mg/mL of nicotine. Additionally, the method has been proven robust and flexible for parameters such as change in flow rate, column oven temperature, and organic phase composition, which proves applicability of the method over wide variety of e-liquids in market.Entities:
Year: 2018 PMID: 30159196 PMCID: PMC6109535 DOI: 10.1155/2018/1720375
Source DB: PubMed Journal: J Anal Methods Chem ISSN: 2090-8873 Impact factor: 2.193
HPLC methods published for analysis of nicotine in e-liquids.
| Type of detection platform used | Validation parameters evaluated | e-Liquids (brand and number of samples) | Reference | Comments |
|---|---|---|---|---|
| HPLC, PDA, C 18 (150 × 4.6 mm, 5 | LOD, LOQ, linearity, accuracy, and precision | Smoking everywhere (15), Njoy (5), and CIXI (10) | Trehy et al. [ | 1. Specificity data are not mentioned |
| 2. Although the method uses PDA detector, no information about peak purity is mentioned | ||||
| 3. Chromatographic integration in the chromatograms published by Trehy et al. is improper, which raises concerns over the specificity of the method | ||||
| HPLC, PDA, C 18 (200 × 4.6 mm, 5 | LOD, LOQ, linearity, accuracy, and precision | Refill fluids (75), do it yourself (1) | Davis et al. And cross-reference of Trehy et al. For the HPLC method [ | |
|
| ||||
| UPLC | Not applicable | e-Liquids (20). Details not mentioned | Etter et al. [ | Method not validated for analysis of e-liquids |
|
| ||||
| UPLC, PDA and MS, C 18 | Linearity | e-Liquids (6). Details not mentioned | Meruva et al. And cross-reference of Trehy et al. for the HPLC method [ | 1. Additional validation details not provided |
| 2. No data about specificity of the method for nicotine in presence of flavoring chemicals | ||||
HPLC chromatographic conditions of the method.
| Chromatographic conditions | |
|---|---|
| Flow rate | 0.8 mL/min |
| Wavelength | 260 nm |
| Stationary phase | Hypersil Gold Phenyl (150 mm × 4.6 mm, 3 |
| Column oven temperature | 25°C |
| Injection volume | 10 |
| Sample cooler temperature | 5°C |
| Run time | 12 min |
HPLC gradient program.
| Pump program | ||||
|---|---|---|---|---|
| Time (min) | A (%) | B (%) | C (%) | D (%) |
| 0 | 60 | 26 | 14 | 0 |
| 4 | 60 | 26 | 14 | 0 |
| 4.1 | 0 | 0 | 0 | 100 |
| 7 | 0 | 0 | 0 | 100 |
| 7.1 | 60 | 26 | 14 | 0 |
| 12 | 60 | 26 | 14 | 0 |
Stressed conditions for e-liquid assay samples, placebos, and blanks.
| Sample stress type | Time | Assay sample (mL) | Water (mL) | 0.1 N·HCl (mL) | 1 N·NaOH (mL) | H2O2 (6%) (mL) |
|---|---|---|---|---|---|---|
| Control | N/A | 4.5 | 0.5 | 0 | 0 | 0 |
| Acid hydrolysis | 30 min | 4.5 | 0 | 0.5 | 0 | 0 |
| Base hydrolysis | 30 min | 4.5 | 0 | 0 | 0.5 | 0 |
| Oxidation | 30 min | 4.5 | 0 | 0 | 0 | 0.5 |
| Thermal | 2 hrs | 4.5 | 0.5 | 0 | 0 | 0 |
Change in organic mobile phase ratio.
| Change parameter | % mobile phase A | % mobile phase B | % mobile phase C |
|---|---|---|---|
| Increase in organic polarity | 60 | 24 | 16 |
| Decrease in organic polarity | 60 | 28 | 12 |
Results of forced degradation of various e-liquid flavors.
| Name of sample | Category | Stressed condition | |||
|---|---|---|---|---|---|
| % control assay | % acid degradation | % base degradation | % oxidation degradation | ||
| Standard | NA | NA | 7.75 | 8.29 | 7.62 |
| QC | NA | 99.39 | ND | ND | 3.5 |
| e-Liquid flavor P | Sweet | 95.98 | ND | ND | 12.2 |
| e-Liquid flavor Q | Menthol | 100.76 | 1.53 | ND | 4.14 |
| e-Liquid flavor R | Tobacco | 103.09 | 4.69 | 5.68 | 7.53 |
| e-Liquid flavor S | Menthol | 100.14 | 2.04 | 3.38 | 10.28 |
| e-Liquid flavor T | Fruit | 96.18 | 1.03 | ND | 2.06 |
| e-Liquid flavor U | Coffee | 97.68 | ND | 1.59 | 4.33 |
| e-Liquid flavor A | Tobacco | 96.19 | 1.94 | 1.00 | 4.75 |
| e-Liquid flavor C | Vanilla | 97.31 | 1.38 | 0.69 | 4.44 |
| e-Liquid flavor E | Fruit | 98.13 | ND | 1.44 | 14.13 |
| e-Liquid flavor G | Fruit | 96.94 | 6.38 | 1.00 | 2.5 |
Note. % degradation of ±1% is considered as no degradation (ND).
Figure 1(a) Representative chromatogram of e-liquid flavor P, a placebo_control. (b) Representative chromatogram of e-liquid flavor P, a sample control. (c) Representative chromatogram of e-liquid flavor P, a sample_oxidation (peroxide degradation).
Accuracy results of the method.
| % spiked level of assay sample | Replicate | % recovery | % mean recovery | % RSD |
|---|---|---|---|---|
| 50 (40 | 1 | 99.95 | 99.44 (39.78 | 0.77 |
| 2 | 99.81 | |||
| 3 | 98.56 | |||
|
| ||||
| 100 (80 | 1 | 99.41 | 100.01 (80.01 | 0.95 |
| 2 | 99.52 | |||
| 3 | 101.11 | |||
|
| ||||
| 150 (120 | 1 | 100.27 | 100.61 (120.73 | 0.39 |
| 2 | 101.04 | |||
| 3 | 100.51 | |||
Robustness.
| Organic phase composition | Sample | Peak area | USP resolution | Purity angle | Purity threshold | |
|---|---|---|---|---|---|---|
| % mobile phase B | % mobile phase C | |||||
| 26 | 14 | e-Liquid flavor V | 1031106 | 1.46 | 0.729 | 1.159 |
| 1031686 | 1.51 | 0.390 | 1.106 | |||
| e-Liquid flavor W | 1023000 | 1.48 | 0.984 | 1.138 | ||
| 1021702 | 1.48 | 0.915 | 1.144 | |||
|
| ||||||
| 28 | 12 | e-Liquid flavor V | 1030040 | 2.31 | 0.192 | 1.063 |
| 1026349 | 2.36 | 0.471 | 1.104 | |||
| e-Liquid flavor W | 1023658 | 2.30 | 0.134 | 1.093 | ||
| 1027008 | 2.28 | 0.295 | 1.128 | |||
Figure 2(a) Full scale representative chromatogram of e-liquid flavor V sample_mobile phase composition B : C, 26 : 14 v/v. (b) Zoomed representative chromatogram of e-liquid flavor V sample_mobile phase composition B : C, 26 : 14 v/v. (c) Full scale representative chromatogram of e-liquid flavor V sample_mobile phase composition B : C, 28 : 12 v/v. (d) Zoomed representative chromatogram of e-liquid flavor V sample_mobile phase composition B : C, 28 : 12 v/v.
Figure 3(a) Full scale representative chromatograph of e-liquid flavor W sample_mobile phase composition B : C, 26 : 14 v/v. (b) Zoomed representative chromatograph of e-liquid flavor W sample_mobile phase composition B : C, 26 : 14 v/v. (c) Full scale representative chromatograph of e-liquid flavor W sample_mobile phase composition B : C, 28 : 12 v/v. (d) Zoomed representative chromatograph of e-liquid flavor W sample_mobile phase composition B : C, 28 : 12 v/v.
Accuracy and precision at LOQ level.
| % spiked level of assay sample | Replicate | % recovery | % mean recovery | % RSD |
|---|---|---|---|---|
| LOQ | 1 | 90.89 | 97.08 | 6.78 |
| 2 | 90.63 | |||
| 3 | 99.22 | |||
| 4 | 103.92 | |||
| 5 | 105.17 | |||
| 6 | 92.64 |
System suitability test.
| Replicate injection | Area | USP tailing | USP plate count |
|---|---|---|---|
| A1 | 1299677 | 1.41 | 8979 |
| A2 | 1295191 | 1.40 | 9211 |
| A3 | 1297765 | 1.40 | 9132 |
| A4 | 1294551 | 1.40 | 9225 |
| A5 | 1291896 | 1.40 | 9194 |
| A6 | 1289339 | 1.39 | 9035 |
| Mean | 1294737 | 1.40 | 9129 |
| Std. dev. | 3768.89 | 0.01 | 101.50 |
| %RSD | 0.29 | 0.45 | 1.11 |
Note. No adjacent peaks were observed at the retention time of nicotine. Hence USP resolution criteria is not applicable.